Visionary Horizons LLC Sells 185 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Visionary Horizons LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,692 shares of the biopharmaceutical company’s stock after selling 185 shares during the quarter. Visionary Horizons LLC’s holdings in Gilead Sciences were worth $526,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of GILD. Empowered Funds LLC increased its position in shares of Gilead Sciences by 55.8% during the fourth quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock worth $20,283,000 after purchasing an additional 78,657 shares in the last quarter. Wilmington Savings Fund Society FSB increased its position in shares of Gilead Sciences by 6.8% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 19,933 shares of the biopharmaceutical company’s stock worth $1,841,000 after purchasing an additional 1,273 shares in the last quarter. Arlington Financial Advisors LLC increased its position in shares of Gilead Sciences by 2.0% during the fourth quarter. Arlington Financial Advisors LLC now owns 47,020 shares of the biopharmaceutical company’s stock worth $4,343,000 after purchasing an additional 915 shares in the last quarter. D Orazio & Associates Inc. increased its position in shares of Gilead Sciences by 39.6% during the fourth quarter. D Orazio & Associates Inc. now owns 4,082 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 1,158 shares in the last quarter. Finally, Kingsview Wealth Management LLC increased its position in shares of Gilead Sciences by 110.9% during the fourth quarter. Kingsview Wealth Management LLC now owns 42,014 shares of the biopharmaceutical company’s stock worth $3,881,000 after purchasing an additional 22,091 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Piper Sandler upped their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Truist Financial upped their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Finally, Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $96.04 on Friday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The stock’s 50-day moving average price is $93.04 and its 200-day moving average price is $86.65.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the firm posted $2.29 EPS. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.